Ecopipam data at MDS 2026 show early and sustained tic reduction in pediatric Tourette syndrome

New data presented at MDS 2026 demonstrate that ecopipam, a dopamine D1 receptor antagonist, significantly reduces tics in pediatric Tourette syndrome patients within 8 weeks and maintains this effect up to 18 months, supporting its potential FDA approval as the first new treatment in over a decade.

This Wire brief sits within Fusion42's coverage of Drug Discovery.